News

While FDA just approved the first drug for primary progressive multiple sclerosis (PPMS), the drug’s price tag is controversial.

Meridian Medical Technologies, Mylan's manufacturing partner for the EpiPen Auto-Injector, expanded a voluntary recall of the EpiPen and EpiPen Jr. epinephrine auto-Injectors to now include additional lots distributed in the United States and other markets.

Chief experience officers improve the patient experience-and the experience of caregivers.

New updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.

From a healthcare perspective, bariatric surgery is considered one of the most effective options for short-term and sustained weight loss. But does the investment pay off?

From public furor over price hikes to the loss of patent protections for blockbuster drugs, big changes are afoot in the pharmaceutical marketplace. Read more.

Just last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more.

Oncology is a complex and rapidly-evolving management challenge for payers.

Biosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.

Weighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.

Last year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.

Patient risk can improve value-based cancer care. Find out how.

How managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.

The correct approach to take when creating a specialty pharmacy network is a key issue for healthcare executives.

Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.

Medical marijuana’s therapeutic evidence base remains nascent and controversial but the regulatory landscape is evolving rapidly.

It’s no surprise that gaps in the screening, monitoring, and management of chronic diseases abound, even in managed care settings. Here’s how technology can help.

A study from Walgreens provides a benchmark of basal insulin treatment persistence across different payers in the United States.

FDA approved the first treatment for metastatic Merkel cell carcinoma (MCC), a rare, aggressive skin cancer.

On March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.

Here are four of the top benefits of incorporating behavioral health management into care management plans for members with chronic conditions.

Here are five key security risk assessment elements to identify and remediate.

Our policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.

Partnership between senior living provider and healthcare system improves population health.

Here are four ways that health plans can improve their internal processes for collecting provider data.

FDA approved safinamide (Xadago, Newron Pharmaceuticals) tablets as an add-on treatment for patients with Parkinson’s disease. FDA also approved new treatments for classical Hodgkin lymphoma and pemphigus vulgaris, a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.

Here are five critical regulations that executives can begin to prepare for today.

Researchers create a set of recommendations for transparency at the agency in five principal areas.

To ensure providers are prepared for telemedicine practice, healthcare leaders must provide training in these areas.

Healthcare leaders are concerned about developing reliable strategies for the future. Is effective strategic and financial planning even possible with so many variables up in the air?